US › Healthcare

INmune Bio Inc (INMB)

US · Healthcare · Biotechnology

$2.18+6.34%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.3M

EPS

$-0.05

EPS estimate

$-0.20

EPS came in at -0.05 against a street estimate of -0.20 — a beat of 75.0%.

Key statistics

Market cap

$64.7M

Forward P/E

0.0

P/B

3.02

Book value

$0.74

EPS (TTM)

$-0.62

52-week high

$2.60

52-week low

$1.09

50-day MA

$2.06

200-day MA

$1.62

Beta

0.94

Analyst view

Analysts rate INmune Bio Inc a buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $7.00.

Shareholding

Insiders

10.75%

Institutions

15.57%

Largest institutional holders

Fund	Stake
BlackRock Inc	4.30%
Vanguard Capital Management, LLC	2.48%
Geode Capital Management, LLC	1.78%
State Street Corp	1.05%
AQR Capital Management LLC	0.97%
UBS Group AG	0.91%
The Goldman Sachs Group Inc	0.83%
Susquehanna International Group, LLP	0.70%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for INmune Bio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.